Efficacy and safety of vildagliptin compared to rosiglitazone in drug naive patients with type 2 diabetes.
Phase of Trial: Phase III
Latest Information Update: 25 May 2017
At a glance
- Drugs Vildagliptin (Primary) ; Rosiglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 04 May 2012 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov record (Parent trial; NCT00099918).
- 02 Oct 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History